Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Moyez Jiwa, Aron Chakera, Ann Dadich, Xingqiong Meng & Epi Kanjo. (2016) The profile of patients with chronic kidney disease who regularly present at an Australian general practice. Current Medical Research and Opinion 32:1, pages 183-189.
Read now
Read now
Vasilios G Athyros, Niki Katsiki, Asterios Karagiannis & Dimitri P Mikhailidis. (2015) Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?. Expert Opinion on Pharmacotherapy 16:10, pages 1449-1461.
Read now
Read now
Vassilios G. Athyros, Asterios Karagiannis, Emmanouel S. Ganotakis, Konstantinos Paletas, Vassilios Nicolaou, George Bacharoudis, Konstantinos Tziomalos, Theodore Alexandrides, Evangelos N. Liberopoulos & Dimitri P. Mikhailidis. (2011) Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Current Medical Research and Opinion 27:8, pages 1659-1668.
Read now
Read now
Articles from other publishers (24)
BinBin Zheng-Lin & Alberto Ortiz. (2018) Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting. Drugs 78:2, pages 215-229.
Crossref
Crossref
Jay S. Skyler, George L. Bakris, Ezio Bonifacio, Tamara Darsow, Robert H. Eckel, Leif Groop, Per-Henrik Groop, Yehuda Handelsman, Richard A. Insel, Chantal Mathieu, Allison T. McElvaine, Jerry P. Palmer, Alberto Pugliese, Desmond A. Schatz, Jay M. Sosenko, John P.H. Wilding & Robert E. Ratner. (2017) Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes 66:2, pages 241-255.
Crossref
Crossref
Wenjia Geng, Ribao Wei, Shuwen Liu, Li Tang, Hanyu Zhu, Pu Chen, Jie Wu, Xueguang Zhang, Fei Zhu, Zhong Yin & Xiangmei Chen. (2016) Shenhua Tablet inhibits mesangial cell proliferation in rats with chronic anti-Thy-1 nephritis. Biological Research 49:1.
Crossref
Crossref
Hassan Al-Thani, Adel Shabana, Ahmed Hussein, Ahmed Sadek, Ahmed Sharaf, Valsa Koshy & Ayman El-Menyar. (2014) Cardiovascular Complications in Diabetic Patients Undergoing Regular Hemodialysis. Angiology 66:3, pages 225-230.
Crossref
Crossref
Ahmed Bakillah, Fasika Tedla, Isabelle Ayoub, Devon John, Allen J. Norin, M. Mahmood Hussain & Clinton Brown. (2015) Plasma Nitration of High-Density and Low-Density Lipoproteins in Chronic Kidney Disease Patients Receiving Kidney Transplants. Mediators of Inflammation 2015, pages 1-11.
Crossref
Crossref
Mirjam Schuchardt, Markus Tölle & Markus van der Giet. 2015. High Density Lipoproteins. High Density Lipoproteins
423
453
.
Anna Marta Schulz, Cindy Terne, Vera Jankowski, Gerald Cohen, Mandy Schaefer, Falko Boehringer, Martin Tepel, Desiree Kunkel, Walter Zidek & Joachim Jankowski. (2014) Modulation of NADPH oxidase activity by known uraemic retention solutes. European Journal of Clinical Investigation 44:8, pages 802-811.
Crossref
Crossref
Chia-Hsuin Chang, Yen-Chieh Lee, Chia-Ti Tsai, Sheng-Nan Chang, Yu-Heng Chung, Min-Shung Lin, Jou-Wei Lin & Mei-Shu Lai. (2014) Continuation of statin therapy and a decreased risk of atrial fibrillation/flutter in patients with and without chronic kidney disease. Atherosclerosis 232:1, pages 224-230.
Crossref
Crossref
Ali Olyaei, Jessica Lassiter & Edgar V. Lerma. 2014. Dyslipidemias in Kidney Disease. Dyslipidemias in Kidney Disease
129
152
.
A. Olyaei, J. L. Steffl, J. MacLaughlan, M. Trabolsi, S. P. Quadri, I. Abbasi & E. Lerma. (2013) HMG-CoA Reductase Inhibitors in Chronic Kidney Disease. American Journal of Cardiovascular Drugs 13:6, pages 385-398.
Crossref
Crossref
Debra L. Weinstein, Laura A. Williams, Dawn M. Carlson, Maureen T. Kelly, Kim M. Burns, Carolyn M. Setze, Aditya Lele & James C. Stolzenbach. (2013) A Randomized, Double-Blind Study of Fenofibric Acid Plus Rosuvastatin Compared With Rosuvastatin Alone in Stage 3 Chronic Kidney Disease. Clinical Therapeutics 35:8, pages 1186-1198.
Crossref
Crossref
F. M. van der Valk, D. F. van Wijk & E. S. G. Stroes. (2012) Serendipity of post-hoc surrogate marker research. European Heart Journal 33:23, pages 2897-2898.
Crossref
Crossref
Boleslaw Rutkowski & Przemyslaw Rutkowski. 2012. Uremic Toxins. Uremic Toxins
163
175
.
Jai Prakash Ojha. (2012) Management of dyslipidemia in CKD, dialysis and renal transplant recipient. Clinical Queries: Nephrology 1:3, pages 191-197.
Crossref
Crossref
Alejandro Gugliucci, Kazuhiko Kotani & Satoshi Kimura. (2012) Paraoxonase 1 in Chronic Kidney Failure. Journal of Lipids 2012, pages 1-10.
Crossref
Crossref
Vasilios G Athyros, Niki Katsiki, Konstantinos Tziomalos & Asterios Karagiannis. (2011) Editorial: Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?. The Open Cardiovascular Medicine Journal 5:1, pages 226-230.
Crossref
Crossref
Ali Olyaei, Erin Greer, Rowena Delos Santos & Jose Rueda. (2011) The Efficacy and Safety of the 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors in Chronic Kidney Disease, Dialysis, and Transplant Patients. Clinical Journal of the American Society of Nephrology 6:3, pages 664-678.
Crossref
Crossref
Glenda C. Gobe, Robert G. Fassett & Jeff S. Coombes. 2011. Nutrients, Dietary Supplements, and Nutriceuticals. Nutrients, Dietary Supplements, and Nutriceuticals
301
314
.
Paulo Cezar Fortes, Jamille Godoy Mendes, Karoline Sesiuk, Letícia Barros Marcondes, Carlos Alberto Mayora Aita, Miguel Carlos Riella & Roberto Pecoits-Filho. (2010) Glycemic and lipidic profile in diabetic patients undergoing dialysis. Arquivos Brasileiros de Endocrinologia & Metabologia 54:9, pages 793-800.
Crossref
Crossref
Joel C. Marrs & Joseph J. Saseen. (2012) Effects of Lipid‐Lowering Therapy on Reduction of Cardiovascular Events in Patients with End‐Stage Renal Disease Requiring Hemodialysis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 30:8, pages 823-829.
Crossref
Crossref
. (2010) Current World Literature. Current Opinion in Cardiology 25:4, pages 411-421.
Crossref
Crossref
Carlos M. Ferrario. (2010) ARBITER 6-HALTS. Does it have the power to settle all matters?. Therapeutic Advances in Cardiovascular Disease 4:2, pages 77-81.
Crossref
Crossref
. (2009) Current World Literature. Current Opinion in Lipidology 20:6, pages 512-519.
Crossref
Crossref
Xiong Z. Ruan, Zac Varghese & John F. Moorhead. (2009) An update on the lipid nephrotoxicity hypothesis. Nature Reviews Nephrology 5:12, pages 713-721.
Crossref
Crossref